This paper is in the following e-collection/theme issue:

Surveillance Systems (430) Public (e)Health, Digital Epidemiology and Public Health Informatics (646) Descriptive Epidemiology and Population Size Estimates (87)

Published on in Vol 8, No 12 (2022): December

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34809, first published .
The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019

The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019

The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019

Authors of this article:

Huilong Chen1 Author Orcid Image ;   Yuan Zhan2 Author Orcid Image ;   Jinxiang Zhang3 Author Orcid Image ;   Sheng Cheng4 Author Orcid Image ;   Yuhao Zhou2 Author Orcid Image ;   Liyuan Chen5 Author Orcid Image ;   Zhilin Zeng1 Author Orcid Image
Article Authors Cited by (17) Tweetations (4) Metrics

Journals

  1. Barbalho S, Laurindo L, Tofano R, Flato U, Mendes C, de Alvares Goulart R, Briguezi A, Bechara M. Dysmetabolic Iron Overload Syndrome: Going beyond the Traditional Risk Factors Associated with Metabolic Syndrome. Endocrines 2023;4(1):18 View
  2. Liu H, Qi J, Yang J, Liu F, Li X, Yin P, Wang L, Liang Z, Wei L, Rao H, Zhou M. Burden of liver complications related to non‐alcoholic fatty liver disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019. Diabetes, Obesity and Metabolism 2023;25(S1):43 View
  3. Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, Ma L, Liu X, Zhou F. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer Journal 2023;13(1) View
  4. Paik J, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi Z. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatology Communications 2023;7(10) View
  5. Li J, Wang Q, Ni W, Liu C, Li Z, Qi X. Global health burden of cirrhosis and other chronic liver diseases (CLDs) due to non-alcoholic fatty liver disease (NAFLD): A systematic analysis for the global burden of disease study 2019. Global Transitions 2023;5:160 View
  6. Tang H, Zhang N, Liu X, Xiao H, Zhang H, Zhou K, Deng J. Incidence Trends of Inherited Anemias at the Global, Regional, and National Levels Over Three Decades. Journal of Epidemiology and Global Health 2023;14(1):72 View
  7. Yu G, Chen Q, Chen J, Liao X, Xie H, Zhao Y, Liu J, Sun J, Chen S. Gut microbiota alterations are associated with functional outcomes in patients of acute ischemic stroke with non-alcoholic fatty liver disease. Frontiers in Neuroscience 2023;17 View
  8. Liang Y, Zhang N, Wang M, Liu Y, Ma L, Wang Q, Yang Q, Liu X, Zhou F, Wei Y. Distributions and Trends of the Global Burden of Colorectal Cancer Attributable to Dietary Risk Factors over the Past 30 Years. Nutrients 2023;16(1):132 View
  9. Yi W, Wu H, Fu W, Feng H, Huang J, Li H, Song Z, Chen Y, Zheng Y, She S. Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease (NAFLD) in Non-Obese Patients with Schizophrenia: A Retrospective Study. Diabetes, Metabolic Syndrome and Obesity 2024;Volume 17:841 View
  10. Allen A, Charlton M, Cusi K, Harrison S, Kowdley K, Noureddin M, Shubrook J. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgraduate Medicine 2024;136(3):229 View
  11. Zhang J, Zhou J, He Z, Li H. Bacteroides and NAFLD: pathophysiology and therapy. Frontiers in Microbiology 2024;15 View
  12. Enomoto H, Akuta N, Hikita H, Suda G, Inoue J, Tamaki N, Ito K, Akahane T, Kawaoka T, Morishita A, Ogawa E, Tateishi R, Yoshiji H. Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021. Hepatology Research 2024 View
  13. Zhang Q, Zhao W, Sun Z, Dong X, Zhu L, Zhang Z, Chen X, Hu Y, Du M, Li J, Zhang Y. Peroxisome proliferator-activated receptors gama ameliorates liver fibrosis in non-alcoholic fatty liver disease by inhibiting TGF-β/Smad signaling activation. Frigid Zone Medicine 2024;4(1):12 View
  14. Al Mahtab M, Shrestha A, Singh S, Anirvan P, Sudhamshu K. Nonalcoholic Fatty Liver Disease vs Metabolic-associated Fatty Liver Disease vs Metabolic Dysfunction-associated Steatotic Liver Disease: What\'s in the Name?. Euroasian journal of hepato-gastroenterology 2024;14(1):1 View
  15. Chan W, Wong V, Adams L, Nguyen M. MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD. Hepatology International 2024 View
  16. Shakhshir M, Zyoud S. Mapping global research trends: Nutrition associations with nonalcoholic fatty liver disease - a Scopus bibliometric analysis. World Journal of Gastroenterology 2024;30(24):3106 View
  17. Malladi N, Lahamge D, Somwanshi B, Tiwari V, Deshmukh K, Balani J, Chakraborty S, Alam M, Banerjee S. Paricalcitol attenuates oxidative stress and inflammatory response in the liver of NAFLD rats by regulating FOXO3a and NFκB acetylation. Cellular Signalling 2024;121:111299 View